This original article, published in JIMD, explores the requirements and recommendations for patients who receive gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency
This case report, published in Child Neurol Open, describes the diagnosis of AADC in a patient with atypical presentation using an epilepsy gene panel
This research article, published in ACNS, evaluates the burden of illness for patients with aromatic L-amino acid decarboxylase (AADC) deficiency and their caregivers
This case report, published in Front Pediatr, describes the genetics, symptoms, treatment and clinical outcomes of 3 patients with aromatic L-amino acid decarboxylase (AADC) deficiency from the Kingdom of Saudi Arabia
This case series, published in the European Journal of Paedriatics, explores the clinical presentation and diagnostic pathway for 16 patients with aromatic L-amino acid decarboxylase (AADC) deficiency in the Middle East. This report is the largest series of patients with confirmed AADC deficiency from this region reported to date
This research article, published in the International Journal of Toxicology, assesses alternative routes of human aromatic L-amino acid decarboxylase (hAADC) enzyme administration in monkeys by evaluating its biodistribution and expression
This case study published in Movement Disorders describes the outcomes of 2 patients with aromatic L-amino acid decarboxylase (AADC) deficiency treated with intraputaminal gene therapy
This research article, published in Orphanet Journal of Rare Diseases, provides insight into the experience of patients with AADC deficiency across 5 different motor function milestone health states
This research article, published in Patient Related Outcome Measures, provides results from a discrete choice experiment to determine health utility values for AADC deficiency, carried out using a sample of the general population in France
This research article, published in Journal of Patient-Reported Outcomes, presents a novel approach to evaluating the impact of AADC deficiency on health-related quality of life
This original study article, published in the Journal of Chromatography B, outlines a study to establish a reliable method to assess both 5-hydroxytryptophan (5-HTP) and 3-O-methyldopa (3-OMD) in dried blood spot (DBS) analysis through ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology, for the biochemical diagnosis of AADC deficiency
This original study article, published in the Current Medical Research and Opinion journal outlines the first qualitative study to understand the symptoms of AADC deficiency and its impact on individuals’ health-related quality of life
This research article, published in Molecular Therapy, presents the results of long-term follow-up from the 3 eladocagene exuparvovec gene therapy trials for aromatic L-amino acid decarboxylase (AADC) deficiency
This perspectives article, published in Current Gene Therapy, describes the low risk of immune response to adeno-associated virus serotype 2 (AAV2) vector-mediated gene therapy to the brain, with support from clinical trial data in aromatic L-amino acid decarboxylase (AADC) deficiency
This research article, published in Journal of Patient-Reported Outcomes, describes the 5-stage development of vignettes describing aromatic L-amino acid decarboxylase (AADC), for use in a subsequent health-state utility elicitation study
This research article, published in Molecular Genetics and Metabolism Reports, evaluates and validates 3-O-methyldopa (3-OMD) as a biomarker for aromatic L-amino acid decarboxylase (AADC) deficiency
This research article, published in Journal of Patient-Reported Outcome Measures, presents an approach specific to France that evaluates the impact of AADC deficiency on health-related quality of life
This case study, published in the Journal of Pediatric Epilepsy, presents a patient with genetically-confirmed aromatic L-amino acid decarboxylase (AADC) deficiency presenting with developmental epileptic encephalopathy (DEE)
This article, published in EMBO Molecular Medicine, describes the role of the putamen as an established target site for gene therapy in treating AADC deficiency and Parkinson’s disease